Dorin Toader
0000-0001-6330-5280
Publication & Citation Trends
Publications
0 total
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells OA
Cited by 19
Semantic Scholar
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide
Cited by 3
Semantic Scholar
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses OA
Cited by 55
Semantic Scholar
Development of a Novel DNA Mono-alkylator Platform for Antibody Drug Conjugates.
Cited by 1
Semantic Scholar
Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCs
Cited by 0
Semantic Scholar
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates OA
Cited by 39
Semantic Scholar
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer OA
Cited by 28
Semantic Scholar
Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios.
Cited by 6
Semantic Scholar
Research Topics
HER2/EGFR in Cancer Research
(72)
Monoclonal and Polyclonal Antibodies Research
(66)
Synthesis and Biological Evaluation
(44)
Radiopharmaceutical Chemistry and Applications
(27)
interferon and immune responses
(24)
Affiliations
AstraZeneca (United Kingdom)
University of Florida
Polymer Research Institute
Altimmune (United States)
AstraZeneca (United States)